<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461746</url>
  </required_header>
  <id_info>
    <org_study_id>ANSGOG-001</org_study_id>
    <nct_id>NCT01461746</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer</brief_title>
  <official_title>A Phase II Trial of Docetaxel/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients, With High-risk Endometrial Carcinoma After Staging Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous some studies suggested the addition of chemotherapy to radiation therapy after
      surgery may have survival benefit in patients with high risk endometrial cancer. In addition,
      docetaxel plus cisplatin regimen may have similar efficacy with paclitaxel plus carboplatin
      which is currently used in most cases. However, docetaxel plus cisplatin may cause less
      toxicity compared to paclitaxel plus carboplatin. Therefore, the investigators aimed to
      analyze the efficacy of docetaxel plus cisplatin regimen followed by radiation therapy after
      surgery in patients with high risk endometrial cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years after completion of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Before each chemotherapy, an expected average of 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months after completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherpay and radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel plus cisplatin followed by radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles</description>
    <arm_group_label>Chemotherpay and radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles</description>
    <arm_group_label>Chemotherpay and radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)</description>
    <arm_group_label>Chemotherpay and radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One of following high risk groups Stage III after staging operation Stage II (Type I
             hysterectomy + BSO + LND) Stage I + two of [Grade III, LVSI+, Mm&gt;1/2] Clear cell or
             serous carcinoma: stage IB-II

          -  Age: 20-75

          -  ECOG PS: 0-2

          -  Adequate organ function BM: WBC ≥ 3,000/mm3, ANC≥1,500/mm3, Plt≥100X103/mm3, Hb≥10.0
             g/dl Kidney: Creatinine &lt;1.25 × UNL이고, GFR ≥ 60 Liver: AST, ALT&lt; 3×UNL, T- bil&lt;1.5 mg/
             mm3

          -  Informed Consent

        Exclusion Criteria:

          -  Previous chemotherapy or pelvic RT

          -  Hormone therapy within 4 weeks

          -  Other malignant disease

          -  Uncontrolled medical disease

          -  Infection requiring antibiotics

          -  Symptomatic CHF, RF, Angina, Arrhythmia, etc.

          -  Neurosis or psychosis

          -  Etc.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
    <phone>+82-10-3010-3633</phone>
    <email>jhnam@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong-Yeol Park, M.D., Ph.D.</last_name>
    <phone>+82-10-3010-3646</phone>
    <email>obgyjypark@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
      <phone>+82-2-3010-3633</phone>
      <email>jhnam@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Jeong-Yeol Park, M.D., Ph.D.</last_name>
      <phone>+82-2-3010-3646</phone>
      <email>obgyjypark@amc.seoul.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <last_update_submitted>May 27, 2017</last_update_submitted>
  <last_update_submitted_qc>May 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Joo-Hyun Nam</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

